Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer

REFERENCES

• Altekruse SF, Kosary CL, Krapcho M, et al. (Eds.). SEER Cancer Statistics Review, 1975–2007. National Cancer Institute. Bethesda, MD. Retrieved from http://seer.cancer.gov/csr/1975_2007/
   Google Scholar
• Jemal A, Tiwari RC, Murray T, Cancer statistics, 2004. CA Cancer J Clin 2004 Jan–Feb;54:8–29.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 Jan 5;354:34–43.
   PubMed Web of Science ®Google Scholar
• Markman M, Markman J, Webster K, Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design. J Clin Oncol 2004 Aug 1;22:3120–3125.
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr., Klug TL, St John E, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 Oct 13;309:883–887.
   PubMed Web of Science ®Google Scholar
• Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984 Dec;50:765–769.
   PubMed Web of Science ®Google Scholar
• Kimura E, Murae M, Koga R, [Clinical significance of new tumor marker CA 125 in gynecological cancer—particularly usefulness in diagnosis of ovarian cancer]. Nippon Sanka Fujinka Gakkai Zasshi 1984 Nov;36:2121–2128.
   Google Scholar
• Amaral VF, Ferriani RA, Sa MF, Positive correlation between serum and peritoneal fluid CA-125 levels in women with pelvic endometriosis. Sao Paulo Med J 2006 Jul 6;124:223–227.
   PubMedGoogle Scholar
• Bairey O, Blickstein D, Stark P, Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma 2003 Oct;44:1733–1738.
   PubMed Web of Science ®Google Scholar
• Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997 Oct 1;9:681–683.
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Zwick C, Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 1998 Apr 28;95:5211–5216.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Altorki NK, Gure AO, Expression of cancer-testis antigens in lung cancer: Definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000 Mar 31;150:155–164.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gordon CM, Williamson B, Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002 Apr 1;98:485–492.
   PubMed Web of Science ®Google Scholar
• Koslowski M, Tureci O, Bell C, Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res 2002 Nov 15;62:6750–6755.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Ritter G, Yin BW, Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. Cancer Immun 2006;6:2.
   Google Scholar
• Bera TK, Saint Fleur A, Lee Y, POTE paralogs are induced and differentially expressed in many cancers. Cancer Res 2006 Jan 1;66:52–56.
   PubMed Web of Science ®Google Scholar
• Nelson PT, Zhang PJ, Spagnoli GC, Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 2007;7:1.
   PubMedGoogle Scholar
• Jungbluth AA, Silva WA, Jr., Iversen K, Expression of cancer-testis (CT) antigens in placenta. Cancer Immun 2007;7:15.
   PubMedGoogle Scholar
• Grizzi F, Franceschini B, Hamrick C, Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3.
   PubMed Web of Science ®Google Scholar
• Coulie PG. Cancer immunotherapy with MAGE antigens. Suppl Tumori 2002 Jul–Aug; 1:S63–S65.
   Google Scholar
• van den Eynde B. [Identification of cancer antigens of relevance for specific cancer immunotherapy]. Bull Mem Acad R Med Belg 2001;156:548–555.
   Google Scholar
• Slingluff CL, Jr., Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med 2005 Apr 29;3:18.
   PubMed Web of Science ®Google Scholar
• Shankar S, Mohapatra B, Suri A. Cloning of a novel human testis mRNA specifically expressed in testicular haploid germ cells, having unique palindromic sequences and encoding a leucine zipper dimerization motif. Biochem Biophys Res Commun 1998 Feb 13;243:561–565.
   PubMed Web of Science ®Google Scholar
• Jagadish N, Rana R, Selvi R, Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J 2005 Jul 1;389(Pt 1):73–82.
   PubMedGoogle Scholar
• Jagadish N, Rana R, Mishra D, Sperm associated antigen 9 (SPAG9): A new member of c-Jun NH2 -terminal kinase (JNK) interacting protein exclusively expressed in testis. Keio J Med 2005 Jun;54:66–71.
   PubMedGoogle Scholar
• Garg M, Chaurasiya D, Rana R, Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 2007 Mar 1;13:1421–1428.
   PubMed Web of Science ®Google Scholar
• Garg M, Kanojia D, Salhan S, Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 2009;115:2671–2683.
   PubMed Web of Science ®Google Scholar
• Kanojia D, Garg M, Gupta S, Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:630–639.
   PubMed Web of Science ®Google Scholar
• Baba T, Azuma S, Kashiwabara S, Toyoda Y. Sperm from mice carrying a targeted mutation of the acrosin gene can penetrate the oocyte zona pellucida and effect fertilization. J Biol Chem 1994 Dec 16;269:31845–31849.
   PubMed Web of Science ®Google Scholar
• Tammela J, Uenaka A, Ono T, OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 2006 Oct;29:903–910.
   PubMed Web of Science ®Google Scholar
• Whitehurst AW, Xie Y, Purinton SC, Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 2010;70:7652–7661.
   PubMed Web of Science ®Google Scholar
• Cox DN, Chao A, Baker J, A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev 1998 Dec 1;12:3715–3727.
   PubMed Web of Science ®Google Scholar
• Deng W, Lin H. Miwi, a murine homolog of piwi, encodes a cytoplasmic protein essential for spermatogenesis. Dev Cell 2002 Jun;2:819–830.
   PubMed Web of Science ®Google Scholar
• Kuramochi-Miyagawa S, Kimura T, Ijiri TW, Mili, a mammalian member of piwi family gene, is essential for spermatogenesis. Development 2004 Feb;131:839–849.
   PubMed Web of Science ®Google Scholar
• Kuramochi-Miyagawa S, Kimura T, Yomogida K, Two mouse piwi-related genes: Miwi and mili. Mech Dev 2001 Oct;108:121–133.
   PubMed Web of Science ®Google Scholar
• Lee JH, Schutte D, Wulf G, Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet 2006 Jan 15;15:201–211.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Shiohama A, Minoshima S, Shimizu N. Identification of eight members of the Argonaute family in the human genome small star, filled. Genomics 2003 Sep;82:323–330.
   PubMed Web of Science ®Google Scholar
• Ke H, Pei J, Ni Z, Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res 2004 Aug 15;298:329–338.
   Google Scholar
• Reed JC. Bcl-2 family proteins. Oncogene 1998 Dec 24;17:3225–3236.
   PubMed Web of Science ®Google Scholar
• Zamzami N, Brenner C, Marzo I, Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 1998 Apr 30;16:2265–2282.
   PubMed Web of Science ®Google Scholar
• Wang QE, Han C, Milum K, Wani AA. Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment. Mutat Res 2011;14:14.
   Google Scholar
• Lethe B, Lucas S, Michaux L, LAGE-1, a new gene with tumor specificity. Int J Cancer 1998 Jun 10;76:903–908.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Jungbluth AA, Stockert E, NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003 Sep 15;63:6076–6083.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005 Dec 20;102:18538–18543.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 Jan 16;348:203–213.
   PubMed Web of Science ®Google Scholar
• Chen YT, Scanlan MJ, Sahin U, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997 Mar 4;94:1914–1918.
   PubMed Web of Science ®Google Scholar
• Karbach J, Gnjatic S, Bender A, Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. Int J Cancer 2010;126:909–918.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Qian F, Matsuzaki J, Vaccinartion with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007 Jul 31;104:12837–12842.
   PubMed Web of Science ®Google Scholar
• Wen Y, Richardson RT, Widgren EE, O'Rand MG. Characterization of Sp17: A ubiquitous three domain protein that binds heparin. Biochem J 2001 Jul 1;357(Pt 1):25–31.
   Google Scholar
• Primakoff P, Myles DG. Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science 2002 Jun 21;296:2183–2185.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Xue Y, Sperm protein 17 (Sp17) in multiple myeloma: Opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunol 2001 Aug;31:2277–2283.
   PubMed Web of Science ®Google Scholar
• Grizzi F, Lim SH, Chiriva-Internati M, Sperm protein 17 is not expressed on normal leukocytes. Blood 2002 May 1;99:3479–3480; author reply 80–1.
   Google Scholar
• Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001 Mar 1;97:1508–1510.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Yu Y, Mirandola L, Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One 2010;5:10471–10484.
   PubMed Web of Science ®Google Scholar
• Vermeij R, Daemen T, de Bock GH, Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010; 891505:15.
   Google Scholar
• Straughn JM, Jr., Shaw DR, Guerrero A, Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004 Mar 1;108:805–811.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Salati E, Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 2002 May 1;94:2447–2453.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Grizzi F, Weidanz JA, A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods 2007 Apr 10;321:86–93.
   PubMedGoogle Scholar
• Nakazato T, Kanuma T, Tamura T, Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer 2007 Mar–Apr;17:426–432.
   Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004 Jan 23;4:1.
   PubMedGoogle Scholar
• Clark J, Rocques PJ, Crew AJ, Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994 Aug;7:502–508.
   PubMed Web of Science ®Google Scholar
• Gure AO, Wei IJ, Old LJ, Chen YT. The SSX gene family: Characterization of 9 complete genes. Int J Cancer 2002 Oct 10;101:448–453.
   PubMed Web of Science ®Google Scholar
• Valmori D, Qian F, Ayyoub M, Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 2006 Jan 15;12:398–404.
   PubMed Web of Science ®Google Scholar
• Michel JJ, Scott JD. AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 2002;42:235–257.
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Srivastava AR, Korsmeyer SJ, Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998 Jun;18:3509–3517.
   PubMed Web of Science ®Google Scholar
• Tortora G, di Isernia G, Sandomenico C, Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 1997 Nov 15;57:5107–5111.
   PubMedGoogle Scholar
• Covens A, Carey M, Bryson P, Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002 Apr;85:71–80.
   PubMed Web of Science ®Google Scholar
• Young M, Plosker GL. Paclitaxel: A pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics 2001;19:1227–1259.
   PubMed Web of Science ®Google Scholar
• Luconi M, Baldi E. How do sperm swim? Molecular mechanisms underlying sperm motility. Cell Mol Biol (Noisy-le-grand) 2003 May;49:357–369.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan S, Liberty GA, Mohan J, Isolation and molecular characterization of AKAP110, a novel, sperm-specific protein kinase A-anchoring protein. Mol Endocrinol 1999 May;13:705–717.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Ono T, Matsushita H, A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis. Int J Cancer 2004 Jan 1;108:86–90.
   PubMed Web of Science ®Google Scholar
• Sharma S, Qian F, Keitz B, A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol 2005 Oct;99:183–188.
   PubMed Web of Science ®Google Scholar
• Meuwissen RL, Offenberg HH, Dietrich AJ, A coiled-coil related protein specific for synapsed regions of meiotic prophase chromosomes. EMBO J 1992 Dec;11:5091–5100.
   PubMed Web of Science ®Google Scholar
• Tammela J, Jungbluth AA, Qian F, SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 2004 Oct 18;4:10.
   PubMedGoogle Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 2004 Dec 9;351:2519–2529.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008 Mar–Apr;58:71–96 Epub 2008 Feb 20.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008 Oct;5:577–587.
   PubMedGoogle Scholar
• Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer May;10:371–378.
   Google Scholar
• Huhtinen K, Suvitie P, Hiissa J, Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009 Apr 21;100:1315–1319.
   PubMed Web of Science ®Google Scholar
• Baldwin P, Laskey R, Coleman N. Translational approaches to improving cervical screening. Nat Rev Cancer 2003 Mar;3:217–226.
   PubMed Web of Science ®Google Scholar
• Visintin I, Feng Z, Longton G, Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065–1072.
   PubMed Web of Science ®Google Scholar
• Kim K, Visintin I, Alvero AB, Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med 2009;29:47–55.
   PubMed Web of Science ®Google Scholar
• Meinhold-Heerlein I, Bauerschlag D, Zhou Y, An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 2007; 13(Pt 1):458–466.
   Google Scholar
• Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10:371–378.
   PubMed Web of Science ®Google Scholar
• Schorge JO, Modesitt SC, Coleman RL, SGO White Paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol 2010 Oct;119:7–17.
   PubMed Web of Science ®Google Scholar
• Old LJ. Cancer/testis (CT) antigens—a new link between gametogenesis and cancer. Cancer Immun 2001 Mar 30;1:1.
   PubMedGoogle Scholar
• Diefenbach CS, Gnjatic S, Sabbatini P, Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008 May 1;14:2740–2748.
   PubMedGoogle Scholar
• Karbach J, Gnjatic S, Bender A, Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. Int J Cancer 2010; Feb 15;126:909–918.
   PubMed Web of Science ®Google Scholar
• Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med 2007;1:513–523.
   PubMed Web of Science ®Google Scholar